|
Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes Clinical research trials and Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes. Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes clinical trial. Human subjects often receive the most effective healthcare possible for their Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes  Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes
Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes
For Condition: Diabetes Mellitus, Non-Insulin-Dependent
Status: Completed
Sponsor(s): Procter & Gamble Pharmaceuticals ,
Synopsis: Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a peson's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 35 Years/70 Years
Genders: Both
Protocol Entry Criteria: - Age 35-70 - Using >20 Units of insulin per day - HbA1c from 6.5% to 10% - No islet antibodies - Otherwise healthy
Total Enrollment:
Location and Contact Information:
Clinical Research Institute of Southern Oregon
Medforo, Oregon, 97504
United States
VA Hospital UCSD
San Diego, California, 92161
United States
University of Texas Health Science Center - Texas Diabetes Institute
San Antonio, Texas, 78207
United States
Diabetes and Endocrine Associates
La Jolla, California, 92037
United States
MedStar Clinical Research Center
Washington D.C., District of Columbia, 20003
United States
Diablo Clinical Research
Walnut Creek, California, 94598
United States
Future Care Studies
Springfield, Massachusetts, 01107
United States
Mountain View Clinical Research
Greer, South Carolina, 29651
United States
DGD Research Associates
San Antonio, Texas, 78229
United States
Piedmont Medical Group
Winston Salem, North Carolina, 27103
United States
Diabetes-Endocrinology Center of WNY
Buffalo, New York, 14209
United States
Mercury Street Medical
Butte, Montana, 59701
United States
UNC Diabetes Care Center
Durham, North Carolina, 27713
United States
Dallas Diabetes and Endocrine Center
Dallas, Texas, 75230
United States
Longmont Medical Research Network
Longmont, Colorado, 80501
United States
Charlottesville Medical Research
Charlottesville, Virginia, 22911
United States
Additional Information:
Study ID Numbers: 2003069;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071422
Other Diabetes Mellitus, Non-Insulin-Dependent Studies:
1. Disease Management and Educational Intervention Outcomes in High-Risk Diabetics
2. LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes.
3. Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination
4. Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients unresponsive to Maximum Dose Metformin & Thiazolidinedione
5. Diabetes Prevention Program
Related Studies:
Other Diabetes Mellitus, Non-Insulin-Dependent Clinical Trials
Other South Carolina Clinical Trials
Other Greer Clinical Trials
Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes
|
|
|
|
|
|
|
|
